Max is an experienced neuroscientist with over 25 years in biotech and pharma, leading drug discovery programs from medicinal chemistry through Phase 2a. He has collaborated with internal teams, CROs, academics, and investors using a stage-gated, decision-driven approach.<\/p>\n\n\n\n
At NeuroSearch, Max worked on CNS and pain projects from early research through clinical development in multi-year pharma collaborations. He later co-founded Saniona, a CNS-focused biotech listed on the Stockholm Nasdaq, serving as Chief Scientific Officer.<\/p>\n\n\n\n
Max also held key roles at Pfizer, strengthening the pain and neuroscience pipeline and capabilities, and at Mundipharma, driving innovation in pain, neuroscience, metabolic disorders, and infectious disease while partnering with commercial teams.<\/p>\n\n\n\n
Alongside his role at Sygnature, Max consults on clinical neuroscience assets and programs for venture capital firms and investment groups worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"
Max Mirza is a neuroscientist who has worked in Biotech, Big & Midsize Pharma for over 25 years, including NeuroSearch, Pfizer, and Mundipharma. He has worked on multiple assets
\nthat have progressed to all stages of clinical development, including Phase 3, in areas of neuroscience, pain, metabolic
\ndisorders, and infectious disease. He was a founder and CSO of the Biotech Saniona (Nasdaq, Stockholm) and
\nconsults for VCs and investment teams on translational and clinical approaches in neuroscience. He has a PhD in
\nNeuroscience from the Institute of Psychiatry, University of London.<\/p>\n","protected":false},"featured_media":9185,"template":"","team_group":[667],"class_list":["post-1414","people","type-people","status-publish","has-post-thumbnail","hentry","team_group-research-management-team"],"acf":[],"yoast_head":"\n